Carregant...

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life

The treatment of hepatitis C virus has changed dramatically with the rapid advent of numerous new antiviral agents, including direct-acting antivirals and agents with non-viral targets (cyclophilin inhibitors, interferon-lambda, vaccine therapy). Given the better safety profile and high antiviral po...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Hepat Med
Autors principals: Pol, Stanislas, Corouge, Marion, Vallet-Pichard, Anaïs
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2016
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4786064/
https://ncbi.nlm.nih.gov/pubmed/27019602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/HMER.S62014
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!